Lurasidone
I'll start with a quick overview while I look up detailed information from the medical library.
Lurasidone is an atypical (second-generation) antipsychotic approved for schizophrenia and bipolar depression. It works primarily as a dopamine D2 and serotonin 5-HT2A antagonist, with additional activity at 5-HT7 and 5-HT1A receptors. It has a favorable metabolic profile compared to many other atypicals - minimal weight gain and low risk of QTc prolongation.
Searching sources...
Reading File
Now let me search the medical library and PubMed in parallel for comprehensive information on Lurasidone.
Finding Sources
Searching PubMed
lurasidone schizophrenia bipolar
Good hits. Now let me read the key sections from both Kaplan textbooks in parallel.
Reading File
Reading File
I have rich content from block43. The second file read missed the lurasidone section. Let me read more of block43 (adverse effects, dosing, special populations) and find the correct Synopsis location for lurasidone.
Reading File
Finding Sources
Excellent - I now have three key sources. Let me read Stahl's section and the Synopsis section in parallel to get mechanistic detail and clinical pearls.
Reading File
Reading File
I now have comprehensive information from multiple authoritative sources. Let me compile the full answer.
Lurasidone (Latuda)
Drug Class & Brand Name
- Class: Second-generation (atypical) antipsychotic - 5-HT2A/D2 antagonist
- Brand name: Latuda
- Available formulations: 20 mg, 40 mg, 80 mg, 120 mg oral tablets
Mechanism of Action
Lurasidone has a multi-receptor pharmacodynamic profile that distinguishes it from many other atypicals:
| Receptor | Action | Clinical Relevance |
|---|---|---|
| D2 (dopamine) | Antagonist (high affinity) | Antipsychotic efficacy; ~60-70% D2 occupancy at 40 mg |
| 5-HT2A (serotonin) | Antagonist (high affinity) | Antipsychotic + antidepressant effect |
| 5-HT7 (serotonin) | Antagonist (high affinity) | Antidepressant properties |
| 5-HT1A (serotonin) | Partial agonist (moderate) | Antidepressant, anxiolytic, reduces EPS |
| α2A, α2C (adrenergic) | Antagonist (moderate) | Potential pro-cognitive effects |
| H1 (histamine) | Negligible affinity | Low sedation, low weight gain |
| M1 (muscarinic) | Negligible affinity | No anticholinergic side effects |
| 5-HT2C | Low affinity | Minimal metabolic impact |
The combination of 5-HT7 antagonism + 5-HT1A partial agonism + 5-HT2A antagonism is thought to underlie its notable antidepressant efficacy in bipolar I depression, as described in Stahl's Essential Psychopharmacology.
FDA-Approved Indications
- Schizophrenia - Adults and adolescents aged 13-17 years
- Major depressive episodes associated with Bipolar I Disorder
- Monotherapy - Adults and pediatric patients (10-17 years)
- Adjunctive therapy with lithium or valproate - Adults
Dosing
| Indication | Starting Dose | Effective Range | Maximum |
|---|---|---|---|
| Schizophrenia | 40 mg once daily | 40-160 mg/day | 160 mg/day |
| Bipolar depression (monotherapy) | 20 mg once daily | 20-120 mg/day | 120 mg/day |
| Bipolar depression (adjunctive) | 20 mg once daily | 20-120 mg/day | 120 mg/day |
Key rule: Must be taken with food (at least 350 calories) - food significantly increases bioavailability. No initial dose titration is required.
Dose adjustments:
- Moderate-to-severe renal impairment: do not exceed 80 mg/day
- Severe hepatic impairment: do not exceed 40 mg/day
- With moderate CYP3A4 inhibitor (e.g., diltiazem): do not exceed 40 mg/day
Pharmacokinetics
| Parameter | Value |
|---|---|
| Oral bioavailability | 9-19% (low; food-dependent) |
| Tmax | 1-3 hours |
| Volume of distribution | 6,173 L (very large) |
| Protein binding | High |
| Metabolism | Primarily CYP3A4 (N-dealkylation, hydroxylation of norbornane ring, S-oxidation) |
| Active metabolites | 2 major active + 2 major inactive |
| Elimination half-life | ~18 hours |
| Route of excretion | Feces (80%), urine (9%) |
NOT a substrate for CYP1A2, CYP2D6, CYP2C9, CYP2C19, or others - simplifying many drug interaction concerns.
Adverse Effects
Common:
- Akathisia (most reported at higher doses)
- Somnolence/sedation (dose at night to minimize)
- Nausea, vomiting, diarrhea
- Extrapyramidal symptoms (parkinsonism)
- Agitation
Favorable metabolic profile (compared to most SGAs):
- Low-to-moderate risk of weight gain
- Minimal effect on glucose and lipids
- This is due to negligible H1 and M1 receptor affinity and low 5-HT2C affinity
Cardiovascular:
- QTc prolongation is modest - 7.5 ms increase at 120 mg; no dose-response relationship observed
- No study participants achieved QTc > 500 ms in clinical trials
- Orthostatic hypotension: ~1.1% of patients
Other serious risks:
- Hyperprolactinemia (class effect)
- Tardive dyskinesia (class effect; highest risk in elderly)
- Neuroleptic malignant syndrome (rare)
- Seizures: 0.1% incidence (premarketing data)
Black Box Warnings
- Increased mortality in elderly patients with dementia-related psychosis (class effect for all SGAs - not approved for this use)
- Suicidal thoughts and behaviors in children, adolescents, and young adults (associated with antidepressant indications)
Contraindications
- Hypersensitivity to lurasidone or any tablet component
- Concurrent use with strong CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil)
- Concurrent use with strong CYP3A4 inducers (rifampin, St. John's wort, phenytoin, carbamazepine)
Drug Interactions
All mediated through CYP3A4:
- Strong CYP3A4 inhibitors (ketoconazole, ritonavir): CONTRAINDICATED
- Moderate CYP3A4 inhibitors (diltiazem, atazanavir, erythromycin, fluconazole, verapamil): Reduce lurasidone dose by half; max 40 mg/day
- Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's wort): CONTRAINDICATED
- Grapefruit / grapefruit juice: Avoid - inhibits CYP3A4
Special Populations
- Pediatric (schizophrenia): Approved age 13+
- Pediatric (bipolar depression): Approved age 10+; one of the preferred agents for this age group due to good tolerability and absence of weight gain
- Elderly / dementia: Carries black box warning; not approved
- Pregnancy / lactation: Use only if benefit outweighs risk
Clinical Pearls
- Bipolar I depression is arguably the primary clinical niche where lurasidone stands out - the 5-HT7/5-HT1A/5-HT2A combination gives robust antidepressant properties. It is often a first-line preferred agent for bipolar depression in the US.
- No titration needed - start at the therapeutic dose
- Night dosing reduces risk of motor side effects and sedation
- It does NOT cause significant anticholinergic side effects, sedation, or weight gain - making it well-tolerated long-term
- A novel combination agent NRX-101 (Cyclurad) - lurasidone + D-cycloserine (a glycine site NMDA receptor antagonist) - is in early clinical development for acute suicidal ideation and bipolar depression
Recent Evidence
A 2026 systematic review and meta-analysis by Ghenciulescu et al. examined the transdiagnostic efficacy of lurasidone on depressive symptoms (PMID: 40831006), published in the British Journal of Psychiatry, supporting broad antidepressant utility across diagnostic categories. A 2026 network meta-analysis by Olgiati et al. (PMID: 41191868) evaluated lurasidone among second- and third-generation antipsychotics for cognitive dysfunction in schizophrenia-spectrum disorders.
Sources: Kaplan & Sadock's Comprehensive Textbook of Psychiatry; Kaplan and Sadock's Synopsis of Psychiatry; Stahl's Essential Psychopharmacology (Neuroscientific Basis); The Maudsley Prescribing Guidelines in Psychiatry, 15th ed.
This is a shared conversation. Sign in to Orris to start your own chat.